INT 230-6

Drug Profile

INT 230-6

Alternative Names: INT-230-6

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intensity Therapeutics
  • Class Cancer vaccines; Platinum complexes; Vinca alkaloids
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Immunostimulants; Natural killer cell receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 27 Feb 2018 Safety data from a phase I/II trial in Cancer released by Intensity Therapeutics
  • 15 Jun 2017 Intensity Therapeutics has patents pending for INT 230-6 in Australia
  • 15 Jun 2017 Intensity Therapeutics receives patent allowance for its DfuseRxSM technology platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top